The privately funded company, which includes an NIH grant, has received FDA approval to undertake a human clinical trial for the extraction of excess mesenteric visceral fat to reverse T2D. The trial will be conducted at The University of Texas Health Science Center at San Antonio upon receipt of Institutional Review Board (IRB) approval. The company's CEO, Edward Gillen, has over 30 years of medical device industry experience, with 15 years business experience in diabetes care and surgical devices.